The company in question is, GlaxoSmithKline plc (NYSE:GSK) currently with a stock price of 43.78 (-0.09% today). The market cap for GlaxoSmithKline plc is 106.76 B, and is in the sector Healthcare, and Drug Manufacturers – Major industry. The target price for GlaxoSmithKline plc is 47.55. Currently GlaxoSmithKline plc is trading with a P/E of 50.21, and a forward P/E of 15.32. Average volume for GlaxoSmithKline plc is 2981.21 and so far today it is 2436222.
Performance in the last year for GlaxoSmithKline plc has been 8.55%. For EPS growth, GlaxoSmithKline plc has seen a growth of -89.20%, and is looking to grow in the next year to 1.24%. More long term stats show that EPS growth has been -28.90% over the last five years and could be 13.10% for the next five years. GlaxoSmithKline plc has seen sales growth quarter over quarter at 18.50%, with EPS growth quarter over quarter at 271.90%. The 20-day simple moving average is 0.49%, with the 200-day simple moving average coming to 6.68%.
Since the IPO date for GlaxoSmithKline plc on the 07/09/1986, GlaxoSmithKline plc has seen performance year to date to be 13.68%. With GlaxoSmithKline plc trading at 43.78, the dividend yield is 4.45%, and the EPS is 0.87.
So could GlaxoSmithKline plc, be undervalued? Well as said before P/E is 50.21. The PEG is 3.83, P/S is 2.88 and the P/B is at 48.64. The P/cash is 18.21, with P/free cash flow at 629.1.
GlaxoSmithKline plc ability to deal with debt shows that the current ratio is 0.9, and the quick ratio is 0.6. This is with long term debt/equity at 8.52, and total debt/equity at 10.7.
In terms of margins, GlaxoSmithKline plc has a gross margin of 68.40%, an operating margin of 12.40% and a profit margin of 5.80%.Payout ratio for GlaxoSmithKline plc is 232.70%. Return on assets come to 2.90% with return on investment coming to 8.60%.
Insider ownership for GlaxoSmithKline plc, is at 0.20% and institutional ownership comes to 9.30%. Outstanding shares are at 2438.5. While shares float is 2435.76. The float short is currently 0.24%, and short ratio is 1.94.
Graphs: GlaxoSmithKline plc NYSE: GSK | Tuesday June 20, 2017
Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.